CRVO

CervoMed Inc. · NASDAQ

Sector Commercial Services
Industry Miscellaneous Commercial Services
Website cervomed.com
Employees(FY) 4
ISIN US15713L1098

Performance

+3.77%

-13.07%

-10.48%

-44.81%

+76.93%

YTD

+84.93%

Profile

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.

Advanced Technical Analysis

Technical Analysis of CRVO 2024-10-11

The stock indicators reflect a bearish sentiment overall, with a Moving Average Score of 10 indicating strong downward pressure, while the Oscillators Score of 53 suggests a neutral stance. The Technical Score of 31 further reinforces the bearish outlook, indicating that caution is warranted in the current market environment.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of CRVO

Stock Rank

Recent News & Updates

2024-10-04 04:49
CervoMed Ends $20 Million Stock Sales Agreement with BTIG(Yahoo Finance)
2024-10-01 20:00
CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference(Globenewswire)
2024-09-25 20:00
CervoMed to Deliver Late-Breaking Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)(Globenewswire)
2024-09-19 15:37
CERVOMED INC (CRVO) Soars 10.6%: Is Further Upside Left in the Stock?(Yahoo Finance)
2024-08-26 20:30
CervoMed to Participate in Upcoming Investor Conferences(Globenewswire)
2024-08-21 20:00
CervoMed Featured in Fortune for Advances in the Treatment of Dementia with Lewy Bodies(Globenewswire)
2024-08-11 20:00
CervoMed Reports Second Quarter 2024 Financial Results and Provides Corporate Updates(Globenewswire)
2024-08-03 21:03
Morgan Stanley Predicts up to ~230% Surge for These 2 Strong Buy Stocks(Yahoo Finance)
2024-07-29 20:00
CervoMed to Participate in The Canaccord Genuity 44th Annual Growth Conference(Globenewswire)
2024-07-28 20:00
CervoMed Announces Presentation at AAIC 2024 on Plasma Biomarker Data That Are Consistent with Neflamapimod Impacting the Underlying Disease Process in Patients with Dementia with Lewy bodies (DLB)(Globenewswire)
2024-07-16 20:00
CervoMed to Participate in the Emerging Growth Conference(Globenewswire)
2024-07-16 19:00
Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now(Globenewswire)
2024-07-15 19:00
Presenting on the Emerging Growth Conference 73 Day 1 on July 17 Register Now(Globenewswire)
2024-07-10 20:51
CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024(Globenewswire)
2024-07-09 22:52
CRVO Stock Earnings: CervoMed Misses EPS, Beats Revenue for Q4 2023(Investorplace)
2024-06-27 18:50
Have 20 Bucks? 7 Low-Priced Stocks That Could Double by 2025(Investorplace)
2024-06-23 20:00
CervoMed Announces Addition to Russell 2000 and Russell 3000 Indexes(Globenewswire)
2024-06-10 20:00
CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies(Globenewswire)
2024-05-19 22:09
CervoMed Names William Elder CFO(Yahoo Finance)
2024-05-19 20:00
CervoMed to Appoint William Elder as Chief Financial Officer(Globenewswire)
2024-05-14 21:54
CRVO Stock Earnings: CervoMed Misses EPS, Beats Revenue for Q1 2024(Investorplace)
2024-05-14 20:00
CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates(Globenewswire)
2024-04-02 19:00
Presenting on the Emerging Growth Conference 69 Day 2 on April 4 Register Now(Globenewswire)
2024-04-01 19:00
Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now(Globenewswire)
2024-03-31 20:00
CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates(Globenewswire)
2024-03-28 04:05
CervoMed to Participate in Upcoming Investor Conferences(Globenewswire)
2024-03-27 20:30
CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors(Globenewswire)
2024-03-04 19:00
CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD 2024(Globenewswire)
2024-02-20 19:00
CervoMed to Participate in the BIO CEO and Investor Conference(Globenewswire)
2024-02-19 21:22
CervoMed appoints drug development veteran Dr. Joshua Boger as Chairman of the Board(Yahoo Finance)

Page 1 of 5

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment.